Experimental compounds to lower intraocular pressure.
Experimental compounds to lower intraocular pressure.
复制标题
降低眼内压的实验化合物。
DOI：
10.1111/j.1442-9071.1989.tb00502.x
复制
发表时间：
1989
期刊：
影响因子：
--
通讯作者：
Serle,JB
中科院分区：
文献类型：
--
作者：
Podos,SM;Camras,CB;Serle,JB
需要一种比目前临床使用的更有效、副作用更少的新的降眼压药物。激光诱导的猴子青光眼模型是测试潜在的降低眼压(IOP)新药的极佳模型。通过二级信使系统或通过酶来降低眼压的各种制剂正在灵长类动物身上进行研究。几种α-肾上腺素能激动剂和拮抗剂对猴子和人类都是有效的降眼压药物。对氨基可乐定是一种α-激动剂，可以抑制激光后人类眼压的短暂上升。前列腺素F2、α-1-异丙酯在青光眼猴眼和青光眼患者的多剂量测试中显著降低眼压。改良的碳酸酐酶抑制剂，旨在提高眼内渗透率，降低局部给药时猴子模型和高眼压患者的单次给药研究中的眼压。研究表明，福斯科林和钒酸盐是治疗青光眼的不太有希望的药物。
A need exists for new ocular hypotensive agents that are more efficacious and that have fewer side effects than those now clinically used. Laser‐induced glaucoma in monkeys is an excellent model to test potential new drugs that lower intraocular pressure (IOP). A variety of agents that act through secondary messenger systems or via enzymes to lower IOP are being investigated in primates. Several alpha‐adrenergic agonists and antagonists are effective ocular hypotensive agents in monkeys and humans. Para‐aminoclonidine, an alpha, agonist, inhibits the transient post‐laser rise of IOP in humans. Prostaglandin F2α‐1‐isopropyl ester significantly reduces IOP when tested in multiple dose fashion in glaucomatous monkey eyes and glaucoma patients. Modified carbonic anhydrase inhibitors, designed to enhance intraocular penetration, reduce IOP in the monkey model and in ocular hypertensive patients in single‐dose studies when given topically. Studies show that forskolin and vanadate are less promising agents for glaucoma therapy.